{"hands_on_practices": [{"introduction": "Accurate genetic counseling is a cornerstone of comprehensive cystic fibrosis care. A common clinical scenario involves assessing the residual risk of being a CF carrier after a negative genetic test, as no test is perfect. This exercise [@problem_id:5131501] provides practice in applying Bayesian reasoning to update a patient's prior, population-based carrier risk with the results of a targeted mutation panel that has known sensitivity, a critical skill for interpreting genetic screening data and counseling families appropriately.", "problem": "A pediatric genetics clinic is counseling a couple in which one partner is a confirmed heterozygous carrier for cystic fibrosis (CF). The other partner is of an ancestry in which the CF carrier frequency is $1/25$. That partner undergoes a targeted CF mutation panel that, in this ancestry, has analytic sensitivity $0.90$ for identifying carriers of CF-causing variants and analytic specificity that can be considered approximately $1.00$ for the purpose of decision-making. The partnerâ€™s panel result is negative.\n\nUsing the core definitions of sensitivity, specificity, and conditional probability, and without invoking any unprovided shortcut formulas, determine the posterior probability that the partner remains a CF carrier after this negative test result. Express your final answer as a decimal number and round to four significant figures. Do not use a percent sign.", "solution": "The problem is well-posed, scientifically grounded, and provides all necessary information to determine the posterior probability. We can proceed with the solution.\n\nLet us define the following events:\n- $C$: The event that the partner is a carrier for cystic fibrosis.\n- $N$: The event that the partner is not a carrier for cystic fibrosis.\n- $T^-$: The event that the partner's mutation panel result is negative.\n- $T^+$: The event that the partner's mutation panel result is positive.\n\nFrom the problem statement, we are given the following probabilities:\n1.  The prior probability that the partner is a carrier, based on their ancestry's carrier frequency, is $P(C) = \\frac{1}{25} = 0.04$.\n2.  The prior probability that the partner is not a carrier is therefore $P(N) = 1 - P(C) = 1 - \\frac{1}{25} = \\frac{24}{25} = 0.96$.\n3.  The analytic sensitivity of the test is the probability of a positive test result given that the person is a carrier: $P(T^+|C) = 0.90$.\n4.  The analytic specificity of the test is the probability of a negative test result given that the person is not a carrier. The problem states this can be approximated as $1.00$, so we take $P(T^-|N) = 1.00$.\n\nOur objective is to calculate the posterior probability that the partner is a carrier given that their test result was negative. This is the conditional probability $P(C|T^-)$.\n\nAccording to the fundamental definition of conditional probability, we have:\n$$P(C|T^-) = \\frac{P(C \\cap T^-)}{P(T^-)}$$\nwhere $P(C \\cap T^-)$ is the joint probability of the partner being a carrier and testing negative, and $P(T^-)$ is the total probability of testing negative.\n\nFirst, we calculate the numerator, $P(C \\cap T^-)$. This can be found using the multiplication rule for conditional probability, $P(A \\cap B) = P(A|B)P(B)$.\n$$P(C \\cap T^-) = P(T^-|C)P(C)$$\nWe need to find $P(T^-|C)$, which is the probability of a negative test given the partner is a carrier. This is also known as the false negative rate. Since a carrier must test either positive or negative, the sum of the probabilities of these two outcomes is $1$.\n$$P(T^+|C) + P(T^-|C) = 1$$\nTherefore,\n$$P(T^-|C) = 1 - P(T^+|C) = 1 - 0.90 = 0.10$$\nNow we can compute the numerator:\n$$P(C \\cap T^-) = P(T^-|C)P(C) = 0.10 \\times 0.04 = 0.004$$\n\nNext, we calculate the denominator, $P(T^-)$, which is the total probability of a negative test. A person can test negative in two mutually exclusive ways: (1) they are a carrier and test negative ($C \\cap T^-$), or (2) they are not a carrier and test negative ($N \\cap T^-$). By the law of total probability:\n$$P(T^-) = P(C \\cap T^-) + P(N \\cap T^-)$$\nWe have already calculated $P(C \\cap T^-) = 0.004$. We now calculate $P(N \\cap T^-)$ using the multiplication rule:\n$$P(N \\cap T^-) = P(T^-|N)P(N)$$\nUsing the given values:\n$$P(N \\cap T^-) = 1.00 \\times 0.96 = 0.96$$\nNow we can sum the probabilities to find the total probability of a negative test:\n$$P(T^-) = 0.004 + 0.96 = 0.964$$\n\nFinally, we substitute the numerator and denominator back into the formula for $P(C|T^-)$:\n$$P(C|T^-) = \\frac{P(C \\cap T^-)}{P(T^-)} = \\frac{0.004}{0.964}$$\nPerforming the division gives:\n$$P(C|T^-) \\approx 0.00414937759...$$\nThe problem requires the answer to be expressed as a decimal number rounded to four significant figures. The first four significant figures are $4$, $1$, $4$, and $9$. The subsequent digit is $3$, which is less than $5$, so we round down (i.e., keep the last significant digit as is).\n$$P(C|T^-) \\approx 0.004149$$", "answer": "$$\\boxed{0.004149}$$", "id": "5131501"}, {"introduction": "The clinical severity of cystic fibrosis is directly linked to the amount of residual function of the CFTR protein. This practice problem [@problem_id:5131465] introduces a simplified quantitative model to connect a patient's genotype to their cellular phenotype. By treating the effects of a gating mutation and a trafficking mutation as independent and additive, this hypothetical exercise demonstrates the fundamental principle that the overall CFTR current is a product of how many channels reach the cell surface and how well those channels open, providing a conceptual bridge between molecular genetics and pathophysiology.", "problem": "A pediatric patient with cystic fibrosis heterozygous for two different variants in the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene is studied to estimate residual epithelial chloride transport at the cellular level. Use the following foundational definitions and assumptions: CFTR-mediated macroscopic current is proportional to the product of the number of functional channels at the cell surface, $N$, the channel open probability, $P_o$, and the single-channel conductance, $\\gamma$, so that for a fixed driving force the whole-cell current satisfies $I \\propto N \\cdot P_o \\cdot \\gamma$. In a diploid cell, channels derived from the two CFTR alleles contribute additively to the total current. Assume that in the wild-type state, each allele contributes equally to surface channel number and has identical open probability and single-channel conductance; assume the single-channel conductance, $\\gamma$, and the driving force are unchanged by the variants considered.\n\nConsider a compound heterozygote with $1$ gating mutation on one allele and $1$ trafficking mutation on the other allele. The gating mutation reduces the channel open probability by a fraction $r_g$ without altering surface density from that allele, and the trafficking mutation reduces the surface channel number by a fraction $r_t$ without altering open probability from that allele. There are no dominant-negative interactions, and the effects of the two alleles on the total current are independent and additive. Take $r_g = 0.77$ and $r_t = 0.58$.\n\nUnder these assumptions and using only the foundational definitions above, calculate the expected residual CFTR function as a decimal fraction of wild-type current. Round your answer to $3$ significant figures. Express the final result as a pure number with no units.", "solution": "The problem requires the calculation of the residual Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) function in a pediatric patient who is a compound heterozygote for two different CFTR variants. The function is measured by the macroscopic epithelial chloride current, $I$. We must express this residual function as a fraction of the normal, wild-type (WT) current.\n\nFirst, we formalize the relationship for the macroscopic current, $I$, as given in the problem statement. The current is proportional to the product of the number of functional channels at the cell surface, $N$, the channel open probability, $P_o$, and the single-channel conductance, $\\gamma$. We can write this as an equation with a proportionality constant, $k$, which incorporates other factors such as the fixed ionic driving force.\n$$I = k \\cdot N \\cdot P_o \\cdot \\gamma$$\n\nNext, we define the wild-type state as a reference. A wild-type individual possesses two identical, fully functional CFTR alleles. The problem states that channels from the two alleles contribute additively and, in the wild-type case, equally to the total current. Let $I_{WT}$ be the total current in a wild-type cell. Let $N_{allele,WT}$ be the number of channels produced by a single wild-type allele, and let $P_{o,WT}$ be the open probability of these wild-type channels. The total number of channels in a wild-type cell is $N_{WT} = 2 \\cdot N_{allele,WT}$.\n\nThe total wild-type current is therefore:\n$$I_{WT} = k \\cdot N_{WT} \\cdot P_{o,WT} \\cdot \\gamma = k \\cdot (2 \\cdot N_{allele,WT}) \\cdot P_{o,WT} \\cdot \\gamma$$\nFor simplicity, we can define the current contribution from a single wild-type allele as $I_{allele,WT} = k \\cdot N_{allele,WT} \\cdot P_{o,WT} \\cdot \\gamma$. Then, the total wild-type current is $I_{WT} = 2 \\cdot I_{allele,WT}$.\n\nNow, we consider the patient, who is a compound heterozygote with one allele carrying a gating mutation and the other carrying a trafficking mutation. The total current in the patient, $I_{patient}$, is the sum of the contributions from these two distinct alleles, as their effects are independent and additive.\n$$I_{patient} = I_{gating\\_allele} + I_{trafficking\\_allele}$$\n\nLet's analyze the contribution from each allele:\n\n1.  The allele with the gating mutation:\n    This mutation reduces the channel open probability, $P_o$, by a fraction $r_g$, but does not alter the number of channels at the surface, $N$.\n    -   Number of channels: $N_{gating} = N_{allele,WT}$\n    -   Open probability: $P_{o,gating} = P_{o,WT} - r_g \\cdot P_{o,WT} = (1 - r_g) \\cdot P_{o,WT}$\n    -   Single-channel conductance, $\\gamma$, is unchanged.\n\n    The current from this allele is:\n    $$I_{gating\\_allele} = k \\cdot N_{gating} \\cdot P_{o,gating} \\cdot \\gamma = k \\cdot N_{allele,WT} \\cdot ((1 - r_g) \\cdot P_{o,WT}) \\cdot \\gamma$$\n    By rearranging, we can express this in terms of the single-allele wild-type current:\n    $$I_{gating\\_allele} = (1 - r_g) \\cdot (k \\cdot N_{allele,WT} \\cdot P_{o,WT} \\cdot \\gamma) = (1 - r_g) \\cdot I_{allele,WT}$$\n\n2.  The allele with the trafficking mutation:\n    This mutation reduces the number of surface channels, $N$, by a fraction $r_t$, but does not alter the open probability, $P_o$, of the channels that do reach the surface.\n    -   Number of channels: $N_{trafficking} = N_{allele,WT} - r_t \\cdot N_{allele,WT} = (1 - r_t) \\cdot N_{allele,WT}$\n    -   Open probability: $P_{o,trafficking} = P_{o,WT}$\n    -   Single-channel conductance, $\\gamma$, is unchanged.\n\n    The current from this allele is:\n    $$I_{trafficking\\_allele} = k \\cdot N_{trafficking} \\cdot P_{o,trafficking} \\cdot \\gamma = k \\cdot ((1 - r_t) \\cdot N_{allele,WT}) \\cdot P_{o,WT} \\cdot \\gamma$$\n    Similarly, this can be expressed in terms of the single-allele wild-type current:\n    $$I_{trafficking\\_allele} = (1 - r_t) \\cdot (k \\cdot N_{allele,WT} \\cdot P_{o,WT} \\cdot \\gamma) = (1 - r_t) \\cdot I_{allele,WT}$$\n\nThe total current in the patient's cell is the sum of the contributions from the two alleles:\n$$I_{patient} = I_{gating\\_allele} + I_{trafficking\\_allele} = (1 - r_g) \\cdot I_{allele,WT} + (1 - r_t) \\cdot I_{allele,WT}$$\nFactoring out $I_{allele,WT}$:\n$$I_{patient} = [(1 - r_g) + (1 - r_t)] \\cdot I_{allele,WT} = (2 - r_g - r_t) \\cdot I_{allele,WT}$$\n\nThe problem asks for the residual function as a fraction of the wild-type current. This is the ratio $\\frac{I_{patient}}{I_{WT}}$.\n$$\\text{Fraction} = \\frac{I_{patient}}{I_{WT}} = \\frac{(2 - r_g - r_t) \\cdot I_{allele,WT}}{2 \\cdot I_{allele,WT}}$$\nThe term $I_{allele,WT}$ cancels, simplifying the expression to:\n$$\\text{Fraction} = \\frac{2 - r_g - r_t}{2}$$\n\nWe are given the values $r_g = 0.77$ and $r_t = 0.58$. Substituting these into the expression:\n$$\\text{Fraction} = \\frac{2 - 0.77 - 0.58}{2}$$\n$$\\text{Fraction} = \\frac{2 - 1.35}{2}$$\n$$\\text{Fraction} = \\frac{0.65}{2}$$\n$$\\text{Fraction} = 0.325$$\nThe problem requests the answer to be rounded to $3$ significant figures. The calculated value of $0.325$ already has exactly three significant figures. Thus, no further rounding is needed.", "answer": "$$\\boxed{0.325}$$", "id": "5131465"}, {"introduction": "Managing exocrine pancreatic insufficiency is fundamental to preventing malnutrition and promoting healthy growth in individuals with cystic fibrosis. Pancreatic Enzyme Replacement Therapy (PERT) must be carefully dosed to optimize fat absorption while avoiding the risk of complications like fibrosing colonopathy. This hands-on practice [@problem_id:5131510] guides you through a core clinical calculation, determining the maximum number of enzyme capsules per meal by adhering to established safety ceilings based on both patient weight and dietary fat intake, a crucial skill for daily CF management.", "problem": "A child with Cystic Fibrosis (CF) and documented exocrine pancreatic insufficiency requires Pancreatic Enzyme Replacement Therapy (PERT) to optimize fat absorption and prevent malnutrition and steatorrhea while avoiding excessive dosing that increases the risk of fibrosing colonopathy. In evidence-based pediatric CF management, per-meal lipase dosing is bounded by two well-tested safety ceilings: a body mass ceiling and a dietary fat ceiling. Let the child's body mass be $m$ (in kg), the fat content of a single meal be $F$ (in g), and the per-meal lipase dose be $U$ (in lipase units). The safety ceilings are the body-mass ceiling $u_{\\mathrm{kg}}$ (in $\\text{units} \\cdot \\text{kg}^{-1} \\cdot \\text{meal}^{-1}$) and the dietary-fat ceiling $u_{\\mathrm{fat}}$ (in $\\text{units} \\cdot \\text{g}^{-1}$), so that any safe dose must satisfy $U \\leq u_{\\mathrm{kg}} \\cdot m$ and $U \\leq u_{\\mathrm{fat}} \\cdot F$. Capsules have a fixed lipase content $U_{c}$ (in units per capsule), and the administered capsule count $n$ must be an integer such that $n \\cdot U_{c} \\leq U_{\\max}$, where $U_{\\max}$ is the maximal allowable lipase dose per meal under both ceilings.\n\nConstruct a per-meal PERT regimen for a child with $m = 20~\\text{kg}$ consuming $F = 30~\\text{g}$ of fat per meal, using dosing ceilings $u_{\\mathrm{kg}} = 2,500~\\text{units} \\cdot \\text{kg}^{-1} \\cdot \\text{meal}^{-1}$ and $u_{\\mathrm{fat}} = 4,000~\\text{units} \\cdot \\text{g}^{-1}$. Assume an available capsule strength of $U_{c} = 25,000~\\text{units/capsule}$. Derive the maximal allowable per-meal lipase dose $U_{\\max}$ from first principles using the constraints above, then determine the largest integer $n$ such that $n \\cdot U_{c} \\leq U_{\\max}$. Express your final answer as the integer number of capsules per meal. No rounding is required. Do not include any units in your final boxed answer.", "solution": "The problem is first validated to ensure it is scientifically grounded, well-posed, and objective. The givens are extracted verbatim: child's body mass $m = 20~\\text{kg}$, meal's fat content $F = 30~\\text{g}$, body-mass dosing ceiling $u_{\\mathrm{kg}} = 2,500~\\text{units} \\cdot \\text{kg}^{-1} \\cdot \\text{meal}^{-1}$, dietary-fat dosing ceiling $u_{\\mathrm{fat}} = 4,000~\\text{units} \\cdot \\text{g}^{-1}$, and capsule lipase content $U_{c} = 25,000~\\text{units/capsule}$. The problem requires finding the largest integer number of capsules, $n$, that can be safely administered. The problem's premises are consistent with established pediatric guidelines for Pancreatic Enzyme Replacement Therapy (PERT) in cystic fibrosis, making it scientifically sound and relevant. All necessary data are provided, the constraints are clear, and the objective is unambiguous. The problem is therefore deemed valid and a solution can be constructed.\n\nThe core of the problem is to determine the maximal allowable per-meal lipase dose, $U_{\\max}$, by adhering to two independent safety constraints. A safe dose, $U$, must satisfy both the body-mass-based ceiling and the dietary-fat-based ceiling. These constraints are expressed as two inequalities:\n$1.$ The dose must not exceed the limit based on the child's mass: $U \\leq u_{\\mathrm{kg}} \\cdot m$.\n$2.$ The dose must not exceed the limit based on the meal's fat content: $U \\leq u_{\\mathrm{fat}} \\cdot F$.\n\nTo satisfy both conditions simultaneously, the dose $U$ must be less than or equal to the minimum of these two upper bounds. The maximal allowable dose, $U_{\\max}$, is therefore the lesser of the two calculated ceilings. This can be expressed formally as:\n$$U_{\\max} = \\min(u_{\\mathrm{kg}} \\cdot m, u_{\\mathrm{fat}} \\cdot F)$$\n\nFirst, we calculate the maximum dose allowed by the body-mass ceiling. Let's denote this limit as $U_{\\text{limit, kg}}$.\n$$U_{\\text{limit, kg}} = u_{\\mathrm{kg}} \\cdot m$$\nSubstituting the given values, $u_{\\mathrm{kg}} = 2,500~\\text{units} \\cdot \\text{kg}^{-1} \\cdot \\text{meal}^{-1}$ and $m = 20~\\text{kg}$:\n$$U_{\\text{limit, kg}} = 2,500 \\cdot 20 = 50,000~\\text{units}$$\n\nSecond, we calculate the maximum dose allowed by the dietary-fat ceiling. Let's denote this limit as $U_{\\text{limit, fat}}$.\n$$U_{\\text{limit, fat}} = u_{\\mathrm{fat}} \\cdot F$$\nSubstituting the given values, $u_{\\mathrm{fat}} = 4,000~\\text{units} \\cdot \\text{g}^{-1}$ and $F = 30~\\text{g}$:\n$$U_{\\text{limit, fat}} = 4,000 \\cdot 30 = 120,000~\\text{units}$$\n\nNow, we determine $U_{\\max}$ by taking the minimum of these two values. The body-mass ceiling is more restrictive in this case.\n$$U_{\\max} = \\min(U_{\\text{limit, kg}}, U_{\\text{limit, fat}}) = \\min(50,000, 120,000) = 50,000~\\text{units}$$\n\nThe final step is to determine the number of capsules, $n$, that can be administered. Since capsules cannot be divided, $n$ must be an integer. The total lipase dose from $n$ capsules is $n \\cdot U_c$, where $U_c$ is the lipase content per capsule. This total dose must not exceed the maximal allowable dose, $U_{\\max}$.\n$$n \\cdot U_c \\leq U_{\\max}$$\n\nWe need to find the largest integer $n$ that satisfies this inequality. We can rearrange the inequality to solve for $n$:\n$$n \\leq \\frac{U_{\\max}}{U_c}$$\nSubstituting the calculated value for $U_{\\max}$ and the given value for $U_c = 25,000~\\text{units/capsule}$:\n$$n \\leq \\frac{50,000}{25,000}$$\n$$n \\leq 2$$\n\nThe problem asks for the largest integer $n$ that satisfies this condition. The largest integer less than or equal to $2$ is $2$. Therefore, the maximal number of capsules that can be administered per meal is $2$.", "answer": "$$\\boxed{2}$$", "id": "5131510"}]}